Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Benhaim

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
The Pharmacogenomics Journal|April 10, 2013
The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapyG Absenger, L Benhaim, J Szkandera, et al.
The Pharmacogenomics Journal|June 12, 2013
Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapyL Benhaim, A Gerger, P Bohanes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2011
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancerM J Labonte, P M Wilson, D Yang, et al.
The Pharmacogenomics Journal|December 10, 2014
Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancerP Bohanes, D Yang, F Loupakis, et al.
The Pharmacogenomics Journal|October 8, 2014
Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancerL Benhaim, W Zhang, T Wakatsuki, et al.
The Pharmacogenomics Journal|February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patientsF Loupakis, C Antoniotti, C Cremolini, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Pharmacogenomics Journal|April 10, 2013
The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapyG Absenger, L Benhaim, J Szkandera, et al.
The Pharmacogenomics Journal|June 12, 2013
Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapyL Benhaim, A Gerger, P Bohanes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2011
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancerM J Labonte, P M Wilson, D Yang, et al.
The Pharmacogenomics Journal|December 10, 2014
Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancerP Bohanes, D Yang, F Loupakis, et al.
The Pharmacogenomics Journal|October 8, 2014
Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancerL Benhaim, W Zhang, T Wakatsuki, et al.
The Pharmacogenomics Journal|February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patientsF Loupakis, C Antoniotti, C Cremolini, et al.
Pageof 2